A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib ...

InnoCare Pharma’s tyrosine kinase 2 (TYK2) inhibitor has hit the main goals of a phase 2 trial in China, sustaining the ...

"Innovent and ASK Pharm to commercialise limertinib for lung cancer" was originally created and published by Pharmaceutical ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

BioAtla, Inc. faces financial challenges but presents promising pipeline projects in cancer treatment, offering opportunities ...

The trial is already enrolling solid tumour patients in the US, with the FDA greenlighting the trial last year.

The School of Dentistry at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) earned the first National Institutes of Health grant under its new Center for Pain ...

The new Center for Pain Therapeutics and Addiction Research of the School of Dentistry at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) earned its first NIH ...

Tyrosine is an amino acid made by the body. It helps generate brain chemicals called neurotransmitters, including dopamine, epinephrine, and norepinephrine. It shows some evidence of improving focus ...

Sumit Sharma, MD, sat down with Sydney Crago of Modern Retina to discuss his presentation on the 3 tyrosine kinase inhibitors ...

Growth factors work by attaching to receptors on the cell surface ... When the growth factor attaches to the outside of the cell it switches the tyrosine kinase ‘on’. This signals the cell to divide.